mov18 ige
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02546921)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mov18 ige
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06547840 | Phase 1 | Sep 3, 2024 | Epsilogen Ltd, University of London |
| NCT02546921 | Phase 1 | Sep 1, 2015 | Cancer Research UK |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Epsilogen Ltd | For profit | 1 | 1 | 1 | 2024 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1